Standard treatment for tuberculosis includes isoniazid, which is an effective first-line anti-tuberculosis drug. Some patients develop drug-induced liver injury during treatment, which may lead to treatment interruption or complications. Genetic variation in the N-acetyltransferase 2 gene influences isoniazid metabolism. Tuberculosis, Isoniazid, NAT 2
Conditions
Interventions
Patients who are registered to receive first-line antituberculosis drugs.
Prevention
pulmonary tuberculosis patients.
Sponsors
None listed
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Patients aged 18 years and older, 2. Patients registered to receive first-line antituberculosis drugs, 3. Patients receiving antituberculosis drugs continuously for at least one week.
Exclusion criteria
Exclusion criteria: 1. Patients with incomplete medical records or insufficient laboratory data required for study analysis. , 2.Patients with pre-existing severe liver dysfunction or chronic liver disease before initiation of anti-tuberculosis treatment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| NAT2 Genotype at 12 months after end of the enrolled Haplotype-Specific PCR | — |
Secondary
| Measure | Time frame |
|---|---|
| Anti-Tuberculosis Drug-Induced Liver Injury at 12 months after end of the enrolled ALT | — |
Countries
Thailand
Contacts
Public ContactSuthatip Anun
Phutthasothorn Hospital
Outcome results
None listed